Process for preparing acyl derivatives
US-2024343680-A1 · Oct 17, 2024 · US
with monocyclic quinoid structure
with monocyclic quinoid structure · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07C50/02 |
| Official title | with monocyclic quinoid structure |
| Display label | with monocyclic quinoid structure |
| Total patents | 26 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2023339835-A1 · Oct 26, 2023 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11746077-B2 · Sep 5, 2023 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11667596-B2 · Jun 6, 2023 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2022220054-A1 · Jul 14, 2022 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2022106248-A1 · Apr 7, 2022 · US
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US-2022055975-A1 · Feb 24, 2022 · US
2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-11174212-B2 · Nov 16, 2021 · US
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US-2021276937-A1 · Sep 9, 2021 · US
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US-11021424-B2 · Jun 1, 2021 · US
Treatment of pervasive developmental disorders with redox-active therapeutics
US-2021128494-A1 · May 6, 2021 · US
Intermolecular reaction of propargyl ethers with dimethylfuran in the presence of gold(I) complexes
US-10815178-B2 · Oct 27, 2020 · US
Treatment of pervasive developmental disorders with redox-active therapeutics
US-10736857-B2 · Aug 11, 2020 · US
Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
US-10370348-B2 · Aug 6, 2019 · US
Method for producing 2,3,5-trimethyl benzoquinone by oxidation of 2,3,6-trimethylphenol
US-10364231-B2 · Jul 30, 2019 · US
Method for production of thymoquinone
US-10138194-B2 · Nov 27, 2018 · US
Method for producing 2,3,5-trimethyl benzoquinone by oxidation of 2,3,6-trimethylphenol
US-2018201599-A1 · Jul 19, 2018 · US
Method for production of thymoquinone
US-2018127345-A1 · May 10, 2018 · US
Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
US-2018105506-A1 · Apr 19, 2018 · US
Method for producing an arene with an aromatic C—N bond ortho to an aromatic C—O bond
US-9856208-B2 · Jan 2, 2018 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07C50/02?
- CPC C07C50/02 is the Cooperative Patent Classification code for “with monocyclic quinoid structure.”
- How many patents are filed under CPC C07C50/02 (with monocyclic quinoid structure)?
- Our database includes 26 publications tagged with this CPC code.
- Is patent activity under CPC C07C50/02 growing?
- Publication counts under this code: 3 in 2023 vs 1 in 2024 (latest complete years).